Mo Alavijeh

Biography

  Dr. Alavijeh worked within the Clinical Neurology Department at the Institute of Neurology, University College London.Mo Alavijeh is a science entrepreneur with over 20 years experience in the pharmaceutical industry, having responsibilities as wide-ranging as R&D and innovation, business development and strategic alliances. His experience covers most therapeutic areas, notably CNS, obesity, diabetes, cardiovascular, infection, cancer and inflammation (asthma and arthritis). Dr. Alavijeh is now a world leading authority in CNS DMPK, with distinctive competence in neuro-pharmacokinetics. He also has extensive experience of drug discovery and has made a significant contribution to the development of drugs and drug candidates targeting amyotrophic lateral sclerosis, cancer, obesity and Parkinson's disease. Prior to co-founding Pharmidex in 2003, a company that has grown into a world leader in CNS solutions powered by NeuroPK®, Dr. Alavijeh was head of drug metabolism, pharmacokinetic and pharmacodynamic (DMPK/PD) at Vernalis Research, before which he was DMPK team leader at Aventis Pharma.

Research Interest

 Neurology